HOME >> MEDICINE >> NEWS
Researchers Identify Candidate Immunosuppressant With Fewer Side Effects

BOSTON-April 22, 1998--Researchers at Harvard Medical School and the Center for Blood Research have identified a peptide that may serve as a template for a drug that can suppress the immune response with fewer side effects than immunosuppressants currently available. In addition to benefiting people who receive organ transplants, a drug based on this agent potentially could be used to treat chronic conditions caused by excessive or inappropriate immune responses, such as asthma, inflammation, allergies, and rheumatoid arthritis. Their findings are published in the April 24 Molecular Cell.

The two main immunosuppressant drugs used today, cyclosporin A and FK506, prevent the rejection of foreign organs or bone marrow by disrupting the signaling pathway that activates T cells. But both drugs can cause kidney and nervous system damage, making them unsuitable for wider clinical application. The newly identified peptide prevents a single, specific step in the immune system's signaling pathway, so researchers anticipate that it will not cause serious side effects.

Anjana Rao, professor of pathology, Patrick Hogan, investigator, and their colleagues at Harvard Medical School and the Center for Blood Research made a peptide that binds to calcineurin, a key molecule in the pathway that transmits signals from the T cell receptor to the nucleus. The key difference between how the peptide and the drugs cyclosporin A and FK506 work is the region on calcineurin where each of these agents bind. Cyclosporin A and FK506 block the active site of calcineurin and prevent it from acting on any other molecules within the cell. The peptide, on the other hand, only blocks specific binding between calcineurin and NFAT (nuclear factor of activated T cells). Other calcineurin functions are unimpeded.

With the peptide in place, calcineurin is unable to bind to the transcription factor NFAT and the signaling pa
'"/>

Contact: Peta Gillyatt
pgillyat@warren.med.harvard.edu
617-432-0443
Harvard Medical School
24-Apr-1998


Page: 1 2

Related medicine news :

1. Researchers search for first sign of congestive heart failure
2. Researchers say breast cancer in Africa may provide clues to the disease in African-Americans
3. Researchers close in on breast cancer vaccine
4. Researchers discover link between insulin and Alzheimers
5. Researchers model brains electrical storm during a seizure
6. Researchers track programs success in curbing aggressive behavior
7. Researchers confirm Vioxx nearly doubled cardiovascular risks in cancer prevention study
8. Researchers offer emergency workers a lifeline
9. Researchers discover genetic variant that may explain why women develop M.S. more than men
10. Researchers map the sexual network of an entire high school
11. Researchers hope monkeys can provide new insights into depression

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/20/2019)... ... 20, 2019 , ... SightMD (or the “Company”), a leading ... strategic partnership with Northern Westchester Ophthalmology, P.C. (“NWO”) and its founding ophthalmologist Morris ... adding the Company’s first location in Westchester County to SightMD’s current footprint of ...
(Date:6/19/2019)... ... June 19, 2019 , ... The number of ... rigorous national standards of performance continues to climb. Today, the Public Health ... 11 local governmental public health departments. With this week's accreditation decisions, tens of ...
(Date:6/19/2019)... Mass. (PRWEB) , ... June 19, 2019 , ... ... 26th annual International Research Congress (IRC) in Marseille, France. The conference ... of state-of-the-art research on facioscapulohumeral muscular dystrophy (FSHD). Nearly 200 researchers, clinicians, industry ...
(Date:6/18/2019)... ... June 18, 2019 , ... EMulate Therapeutics, Inc. ... serious diseases, announced it has received notice that the US Food and Drug ... (HDE) for the Hælo Pediatric system. The FDA granted the Humanitarian Use ...
(Date:6/18/2019)... ... June 18, 2019 , ... ... today announced Steve Einig has joined the organization in the newly created role ... initiatives around market engagement, marketing, strategic events and brand management. , “Steve brings ...
Breaking Medicine News(10 mins):
(Date:6/16/2019)... R.I. (PRWEB) , ... June 15, 2019 , ... ... that afflicts 1.4% of the global population. The condition is characterized by ... further medical complications including thyroid disease, anemia, osteoporosis, fertility problems and some cancers, ...
(Date:6/14/2019)... ... June 14, 2019 , ... Akara ... Life Sciences Manufacturers accurately project their contracted liabilities with payers, providers and ... forecasting of rebates and discounts and dynamic scenario modeling in the ever-changing ...
(Date:6/13/2019)... ... June 13, 2019 , ... BESANA Health & Wellness ... center dedicated to realizing your optimal health, inside and out. Created by plastic ... Health & Wellness offers a range of wellness services, including functional health, physical ...
Breaking Medicine Technology:
Cached News: